MyMD Pharmaceuticals, Inc. Stock Price, News & Analysis

MyMD Pharmaceuticals has formed a joint venture with Genomma Lab to develop Oravax's oral COVID-19 vaccine candidate in Mexico. This partnership leverages Genomma's distribution networks in Latin America. Oravax's vaccine aims to be a pioneering oral solution, potentially easier to distribute than traditional injections. The global COVID-19 vaccine market is anticipated to reach $25 billion by 2024, with significant opportunities in Latin America. Oravax has also received regulatory approval to initiate clinical trials in South Africa and is preparing for trials in Israel.

MyMD Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase 2 trial of MYMD-1, a patented drug aimed at delaying aging. This marks a significant milestone as it is believed to be the only IND application of its kind approved by the FDA. Recruitment for the trial is starting immediately, with efficacy data expected by the end of Q1 2022. MYMD-1 aims to reduce inflammation-related proteins and target root causes of aging, positioning itself for a lucrative market projected to reach over $600 billion by 2025.

MyMD Pharmaceuticals (NASDAQ: MYMD) announced that Dr. Chris Chapman, its President and CMO, will be recognized as the Medical Honoree of 2021 by the Arthritis Foundation at the Commitment to a Cure Gala on October 28, 2021, in Washington, D.C. The gala supports efforts to combat arthritis, a condition affecting over 54 million Americans. MYMD-1, MyMD's lead drug candidate, targets aging and autoimmune diseases like rheumatoid arthritis, with Phase 2 trials set to begin. MYMD-1 aims to regulate pro-inflammatory cytokines, offering potential new treatments amid rising arthritis prevalence.

MyMD Pharmaceuticals (Nasdaq: MYMD) will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021, at 4:30 p.m. ET. The Chief Scientific Officer, Adam Kaplin, M.D., Ph.D., will discuss MYMD-1 and Supera-CBD, two promising drug candidates aimed at treating aging disorders and other conditions. MYMD-1 targets TNF-α to regulate inflammation and is set for two Phase 2 trials. Supera-CBD, a synthetic CBD derivative, aims to address anxiety, pain, and neurodegeneration.

MyMD Pharmaceuticals announced the launch of two simultaneous Phase 2 trials for MYMD-1 this quarter, focusing on its ability to extend healthy lifespan and address COVID-19-associated depression. The trial results will be crucial for evaluating MYMD-1's potential as an immunometabolic regulator. The Company will also present its product pipeline at the Benzinga Rising Stars Conference on October 7, 2021, showcasing MYMD-1 and Supera-CBD, a synthetic CBD derivative targeting chronic pain and addiction.

MyMD Pharmaceuticals (NASDAQ: MYMD) announced promising new data on Supera-CBD, its patented synthetic cannabidiol derivative, demonstrating it is 8,000 times more potent than regular CBD. Supera-CBD targets CB2 receptors, linked to beneficial therapeutic effects such as anxiety and neuroprotection, without the psychotropic effects associated with CB1. The company aims to position Supera-CBD as a prescription drug alternative amidst strong market potential for treating conditions like Alzheimer's and neuropathic pain. Dr. Adam Kaplin and Dr. Chris Chapman highlight the drug's ability to activate CB2 at low non-toxic doses.

MyMD Pharmaceuticals (Nasdaq: MYMD) is set to initiate dosing in a Phase 2 trial for MYMD-1, targeting the reduction of TNF-α to potentially delay aging and extend lifespan. The trial will start in Q4 2021, with interim results expected in Q1 2022. MYMD-1 aims to differentiate itself as the first oral TNF-α inhibitor, addressing chronic inflammation—a key aging factor. The market for aging-related treatments is projected to exceed $600 billion by 2025, underscoring the potential growth for MYMD-1.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) will showcase its development pipeline at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13-15, 2021. The presentation, accessible on-demand from 7:00 am ET on September 13, will feature Dr. Chris Chapman and Dr. Adam Kaplin discussing MyMD-1 and Supera-CBD. MYMD-1 aims to treat aging, autoimmune diseases, and COVID-19-related conditions, while Supera-CBD targets anxiety, chronic pain, and addiction, progressing toward human trials.

MyMD Pharmaceuticals (Nasdaq: MYMD) announced the issuance of U.S. Patent No. 11,096,933, securing methods for administering MYMD-1 to treat chronic inflammation-related disorders, particularly fibrosis and asthma. This patent marks the thirteenth supporting MYMD-1's development as a treatment for autoimmune and age-related diseases. The compound has shown potential in regulating the immune system and addressing diseases like idiopathic pulmonary fibrosis, which affects nearly 100,000 individuals in the U.S.